Camrelizumab
PD1 | |
---|---|
Clinical data | |
Other names | SHR-1210 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII |
Camrelizumab (SHR-1210) (
INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2]
This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019[update], camrelizumab is undergoing
III
trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- S2CID 141482897.